Development of a mass spectrometry-enabled assay for the identification of new cellular targets for antibody-drug conjugates that utilize a novel payload delivery mechanism

点击翻译按钮获取中文摘要

ImmunoBiochem has developed a disruptive technology that will revolutionize the field of Antibody-Drug Conjugate (ADC) therapeutics. ADCs comprise a novel class of targeted therapeutics that combine the high specificity of monoclonal antibodies with highly-potent chemotherapeutic small-molecule drugs, and are able to selectively and efficaciously deliver a toxic payload to cancer cells. ImmunoBiochems next-generation ADCs for oncology utilize a novel approach that enables the targeting of solid tumors based on intracellular tumor antigens or cancer biomarkers that are considered undruggable and inaccessible to targeted biological therapeutics. ImmunoBiochems lead ADCs, IMB-101 and IMB-102, are targeted at an undisclosed intracellular tumor antigen that is a clinically-validated cancer biomarker, and offer superior selectivity for cancer cells compared to conventional receptor-targeted ADCs. IMB-101 and IMB-102 thus offer a superior safety profile and broad therapeutic window, preventing on-target toxicities against normal, healthy cells that are common with many ADCs, including the clinically approved ADC, trastuzumab DM1 (Kadcyla®). IMB-101 and IMB-102 are being developed for Triple-Negative Breast Cancer (TNBC), an aggressive disease for which no targeted biological therapeutic treatment options are currently available. The proposed work will enable ImmunoBiochem to leverage academic expertise in mass spectrometry and quantitative onco-proteomics to develop and validate an assay for the discovery of new cellular targets for ADC therapeutics that can take advantage of ImmunoBiochems new payload delivery mechanism.